Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 1Phase 1 1

Status

Recruiting 3Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 5

Conditions

Carcinoma, Non-Small-Cell Lung 481Neoplasms 294Breast Neoplasms 282Colorectal Neoplasms 225Neoplasm Metastasis 191Prostatic Neoplasms 172Ovarian Neoplasms 165Lung Neoplasms 155Multiple Myeloma 153Recurrence 133Melanoma 117Pancreatic Neoplasms 114Squamous Cell Carcinoma of Head and Neck 105Stomach Neoplasms 98Endometrial Neoplasms 98Leukemia, Myeloid, Acute 96Small Cell Lung Carcinoma 85Leukemia, Lymphocytic, Chronic, B-Cell 83Lymphoma, Non-Hodgkin 82Triple Negative Breast Neoplasms 81Carcinoma, Renal Cell 81Carcinoma, Hepatocellular 80Urinary Bladder Neoplasms 75Lymphoma, Large B-Cell, Diffuse 73Lymphoma, Follicular 67Advanced Solid Tumors 64Lymphoma 62Glioblastoma 60Parkinson Disease 4, Autosomal Dominant Lewy Body 56Head and Neck Neoplasms 54

Interventions

Injections 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Malignant Solid Tumor × 90 days × Clear all
NCT07594028 2026-05-18

Phase I/II Study of SCTB41 Plus SCTB39-1with or Without Standard Therapy in Advanced Solid Tumours

Sinocelltech Ltd.

Phase 1/2 Not yet recruiting
126 enrolled
Other solid neoplasm

Advanced Malignant Solid Tumor

NCT07541001 2026-04-23

China Phase II

Intra-IMMUSG Pte Ltd

Phase 2 Active not recruiting
60 enrolled
Other solid neoplasm

Advanced Malignant Solid Tumor

NCT07326488 2026-04-13

A Study of MHB009C in Patients With Advanced Solid Tumors

Minghui Pharmaceutical (Hangzhou) Ltd

Phase 1/2 Recruiting
200 enrolled
Other solid neoplasm

Advanced Malignant Solid Tumor

NCT07192107 2026-04-09

A Study of MHB042C in Patients With Advanced Solid Tumors

Minghui Pharmaceutical (Hangzhou) Ltd

Phase 1/2 Recruiting
200 enrolled
Other solid neoplasm

Advanced Malignant Solid Tumor

NCT07262164 2026-03-25

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors

Virogin Biotech Ltd.

Phase 1 Recruiting
30 enrolled
Other solid neoplasm

Advanced Malignant Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡